![]() ![]() Various important factors, including the risks and uncertainties described under Actual results may differ materially as a result of The estimated savings, reductions, charges and costs noted above are subject toĪ number of assumptions. The Cleansing Materials are based solely on information available to the Materials is furnished herewith as Exhibit 99.2 to this Current Report on FormĨ-K. Occurrence of certain events as set forth in the NDAs. Pursuant to the NDAs, the Company has agreed to publiclyĭisclose certain information, including the Cleansing Materials, upon the In connection with the decision, Endo delivered materials pursuant toĬonfidentiality agreements (the "NDAs") entered into by the Company (the Ordinary course however, out of an abundance of caution, the Company will seekĮntry of an order from the United States Bankruptcy Court for the Southernĭistrict of New York approving this decision as a reasonable exercise of the The Company believes that it is authorized to make this decision in the To $20 million of cash costs related to employee separation costs and otherĬharges. Impairment charges of approximately $220 million to $230 million and $15 million These estimated restructuring charges primarily consist of non-cash asset Production and sales of QWO®, Endo expects to incur total pre-tax restructuringĬharges of approximately $235 million to $250 million in the fourth quarterĢ022. Workforce of approximately 90 full-time positions. This decision is expected to result in annualized pre-tax cash savings ofĪpproximately $50 million to $60 million and a reduction to Endo's global Of bruising following initial treatment as well as the potential for prolonged Histolyticum-aaes) in light of market concerns about the extent and variability Production and sale of Endo Aesthetics' QWO® (collagenase clostridium Indirect subsidiaries, "Endo" or the "Company") announced that it will cease the On December 6, 2022, Endo International plc (together with its direct and ![]() Costs Associated with Exit or Disposal Activities. In the past, Endo International has posted flexible employment opportunities in the form of full-time, remote jobs.Item 2.05. ![]() Eligible employees receive competitive benefits designed to support employee health, financial wellness, work-life balance, and professional development. ![]() As an employer, Endo International seeks results-oriented problem solvers who communicate well and know how to take initiative. headquarters in Malvern, Pennsylvania, with additional offices in New Jersey, Pennsylvania, New York, Alabama, North Carolina, California, Michigan, Connecticut, the United Kingdom, India, Canada, Mexico, and South Africa.įounded in 1997 with the acquisition of assets from The DuPont Merck Pharmaceutical Company, Endo International grew rapidly over the years and today employs a global staff of more than 6,000 people. With global headquarters in Dubin, Leinster, Ireland, Endo International maintains U.S. Relying on internal research and development, licensing, and marketing and advertising, Endo International is committed to improving patients’ lives while consistently creating value for its shareholders. Endo International develops, produces, markets, and distributes generic and branded pharmaceutical products and over-the-counter medications via its five operating companies, which include Par Pharmaceutical, Endo Pharmaceuticals, Paladin Labs, Litha, and SOMAR. Researched & Written by Jessica Howington on the FlexJobs TeamĮndo International is a publicly traded specialty healthcare company that is dedicated to improving the lives of patients through its broad range of products and services. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |